




### SCHEME 5

- Compounds of FORMULA I, wherein  $X_1$  is  $CH_2$  are prepared starting with commercially accessible intermediate  $A_{11}$ . Reduction of the carboxylic acid functionality in  $A_{11}$  with e g; diborane or lithium aluminum hydride gives the hydroxymethyl derivative which may be elaborated to  $CH_2CO_2R$  functionality using the methodology elaborated in EXAMPLE 1.
- Demethylation of the intermediate with a boron trihalide such as boron tribromide, boron trichloride gives the demethylated intermediates  $A_{13}$  which is processed to the compounds of Formula I by synthetic transformations as outlined in SCHEME 1

09082186 061503

# **SCHEME 6**



## SCHEME 6



The compounds of FORMULA I, wherein A<sup>1</sup> is substituted pyridyl may be prepared by adopting the general synthetic SCHEME 6. For example, reaction of substituted 2-halopyridine N-oxide (such as A<sub>19a</sub>-A<sub>19d</sub>) with e. g. 3-aminopropanol gives the intermediates A<sub>20a</sub>-A<sub>20d</sub>. This reaction may preferentially be carried out by refluxing the intermediate 2-halopyridine N-oxide (such as 2-chloropyridine N-oxide) in solvents such as tert-butyl alcohol, tert-amyl alcohol in the presence of base (such as sodium bicarbonate, sodium carbonate, potassium carbonate, potassium bicarbonate). The preparative conditions described in WO 99/15508 (PCT US 98/19466) may be used for this transformation.

Coupling of the intermediates A<sub>20a</sub>-A<sub>20d</sub> with A<sub>16</sub> using Mitsunobu reaction gives the compounds containing the ether link. This reaction may preferentially be carried out using triarylphosphine (such as triphenylphosphine) and dialkylazodicarboxylate (such as diethyl azodicarboxylate, di-tert-butyl azodicarboxylate, di-iso-propyl azodicarboxylate) in solvents such as DMF, methylene chloride, or THF. N-Deoxygenation of resulting intermediates followed by hydrolysis of the ester gives the compounds (A<sub>21a</sub>-A<sub>21d</sub>).




Reduction of the N-oxide bond may be accomplished using e. g., transfer hydrogenation (cyclohexene/Pd on carbon) or ammonium formate and Pd on carbon. The nitro group in A<sub>21d</sub> may be hydrogenated using Pd on carbon or Pt on carbon as catalysts. This transformation may be carried out using solvents such as methanol, ethanol or THF. The hydrolysis of the ester group may be carried using aqueous base (such as sodium hydroxide, lithium hydroxide or potassium hydroxide) in solvents such as methanol, ethanol and THF.

Compounds of Formula I containing a heterocycle other than pyridyl can also be prepared using the methodology of SCHEME 6. For example reaction of 2-bromopyrimidine or 1-chloroisoquinoline N-oxide with 3-aminopropanol gives the analogous intermediates as obtained in STEP 1 of SCHEME 6. The resulting intermediates could be elaborated as in SCHEME

# SCHEME 7



1. Mitsunobu
2. Deprotection
3. Hydrolysis




00000100-001501

## SCHEME 7

- Compounds of FORMULA I containing 6-amino substituents may be prepared as shown in SCHEME 7. The intermediate A<sub>22b</sub> can be prepared as described in J. Med. Chem 43, 22, 2000. Boc-protected 2-amino-6-picoline (A<sub>22a1</sub>) or its ethylated derivative (A<sub>22c1</sub>) are elaborated to A<sub>22a</sub> and A<sub>22c</sub> as shown for case A<sub>22b</sub> in the above publication. The ethylated intermediate A<sub>22c1</sub> may be prepared from A<sub>22a1</sub> by alkylation using e. g.; EtI and a base such as potassium carbonate, cesium carbonate. This reaction may preferentially be carried out in polar solvents such as dimethylformamide, or dimethylacetamide. Mitsunobu reaction of A<sub>16</sub>, gives the compounds containing the phenol ether. Removal of Boc group using e. g., trifluoroacetic acid, in solvents such as dichloromethane, followed by hydrolysis of the ester group as discussed in SCHEME 6 above gives the compounds (A<sub>23a</sub>-A<sub>23c</sub>).

### EXAMPLE A

2-[3-hydroxy-1-propylamino]pyridine-*N*-oxide:




5

- A mixture of 2-chloropyridine-*N*-oxide ( 16.6 g, 100 mmoles), 3-amino-1-propanol ( 15.3 ml, 200 mmoles ),  $\text{NaHCO}_3$  ( 42 g, 0.5 mole ), and tert-amyl alcohol ( 100 ml ) was heated to reflux. After 23 hours, the reaction was
- 10 cooled, diluted with  $\text{CH}_2\text{Cl}_2$  ( 300 ml ), and filtered to remove insoluble materials. The filtrate was concentrated to afford a brown oil. The oil was dried under vacuum overnight. Ether (100 ml) was added to give a brown solid. The ether was decanted and the solid was washed further with ether/acetonitrile (3/1). The resulting solid was heated at  $67^\circ\text{C}$  under
- 15 vacuum to give the desired product (13.5 g).  $^1\text{H}$  NMR was consistent with the proposed structure.

EXAMPLE 33

(1-Methoxymethyl-2-{4-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-phenyl}-cyclopropyl)-acetic acid

5



The title compound is prepared according to the general procedures described in SCHEME 8.

10


09062406.061101



EXAMPLE 34

(1-Methanesulfonylmethyl-2-{4-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-phenyl}-cyclopropyl)-acetic acid

5



The title compound is prepared according to the general procedures described in SCHEME 8.


10

09002105-051501

EXAMPLE 35

(1-Pyridin-3-yl-2-(4-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-phenyl)-cyclopropyl)-acetic acid

5




The title compound is prepared according to the general procedures described in SCHEME 8.

10

0000105-051501  
F05790-0012000

**EXAMPLE 36**


(1-(2,3-Dihydro-benzofuran-6-yl)-2-(4-[2-(5,6,7,8-tetrahydro-  
[1,8]naphthyridin-2-yl)-ethoxy]-phenyl)-cyclopropyl)-acetic acid



The title compound is prepared according to the general procedures described in SCHEME 8.

0000100-001501  
T05100" 00000000

5




10

[illegible]

-131-

5




10

THE  
LIBRARY  
OF THE  
MUSEUM OF  
COMPARATIVE ZOOLOGY  
AT  
HARVARD UNIVERSITY  
CAMBRIDGE, MASSACHUSETTS  
U.S.A.

-132-


5



**10.**

# SECRET

5




10

姓名	性别	年龄	籍贯	职业	住址	备注
王德胜	男	45	山东	工人	XX路XX号	
李秀英	女	38	河北	教师	XX街XX号	
张国强	男	52	河南	农民	XX村XX组	
赵子龙	男	28	湖北	学生	XX路XX号	
陈美华	女	41	江苏	医生	XX街XX号	
周大伟	男	35	浙江	工程师	XX路XX号	
吴小芳	女	25	安徽	护士	XX街XX号	
孙志明	男	58	江西	退休	XX路XX号	
郑丽娟	女	32	湖南	会计	XX街XX号	
冯小刚	男	48	山西	商人	XX路XX号	
马海燕	女	30	陕西	记者	XX街XX号	
徐建刚	男	40	四川	程序员	XX路XX号	
黄晓梅	女	22	广东	实习生	XX街XX号	
郭伟明	男	55	广西	教授	XX路XX号	
梁小红	女	33	福建	设计师	XX街XX号	
周国强	男	43	云南	司机	XX路XX号	
吴小华	女	27	贵州	文员	XX街XX号	
孙志明	男	50	海南	船长	XX路XX号	
郑丽娟	女	31	重庆	歌手	XX街XX号	
冯小刚	男	46	四川	画家	XX路XX号	
马海燕	女	29	湖南	舞蹈家	XX街XX号	
徐建刚	男	39	湖北	作家	XX路XX号	
黄晓梅	女	21	江西	模特	XX街XX号	
郭伟明	男	54	浙江	科学家	XX路XX号	
梁小红	女	34	安徽	律师	XX街XX号	
周国强	男	44	江苏	医生	XX路XX号	
吴小华	女	26	山东	护士	XX街XX号	
孙志明	男	49	河南	教授	XX路XX号	
郑丽娟	女	30	河北	记者	XX街XX号	
冯小刚	男	45	山西	程序员	XX路XX号	
马海燕	女	28	陕西	实习生	XX街XX号	
徐建刚	男	38	四川	商人	XX路XX号	
黄晓梅	女	20	广东	学生	XX街XX号	
郭伟明	男	53	广西	退休	XX路XX号	
梁小红	女	32	福建	会计	XX街XX号	
周国强	男	42	云南	司机	XX路XX号	
吴小华	女	25	贵州	文员	XX街XX号	
孙志明	男	51	海南	船长	XX路XX号	
郑丽娟	女	29	重庆	歌手	XX街XX号	
冯小刚	男	47	四川	画家	XX路XX号	
马海燕	女	27	湖南	舞蹈家	XX街XX号	
徐建刚	男	37	湖北	作家	XX路XX号	
黄晓梅	女	19	江西	模特	XX街XX号	
郭伟明	男	52	浙江	科学家	XX路XX号	
梁小红	女	31	安徽	律师	XX街XX号	
周国强	男	41	江苏	医生	XX路XX号	
吴小华	女	24	山东	护士	XX街XX号	
孙志明	男	48	河南	教授	XX路XX号	
郑丽娟	女	28	河北	记者	XX街XX号	
冯小刚	男	44	山西	程序员	XX路XX号	
马海燕	女	26	陕西	实习生	XX街XX号	
徐建刚	男	36	四川	商人	XX路XX号	
黄晓梅	女	18	广东	学生	XX街XX号	
郭伟明	男	50	广西	退休	XX路XX号	
梁小红	女	30	福建	会计	XX街XX号	
周国强	男	40	云南	司机	XX路XX号	
吴小华	女	23	贵州	文员	XX街XX号	
孙志明	男	49	海南	船长	XX路XX号	
郑丽娟	女	27	重庆	歌手	XX街XX号	
冯小刚	男	46	四川	画家	XX路XX号	
马海燕	女	25	湖南	舞蹈家	XX街XX号	
徐建刚	男	35	湖北	作家	XX路XX号	
黄晓梅	女	17	江西	模特	XX街XX号	
郭伟明	男	51	浙江	科学家	XX路XX号	
梁小红	女	29	安徽	律师	XX街XX号	
周国强	男	39	江苏	医生	XX路XX号	
吴小华	女	22	山东	护士	XX街XX号	
孙志明	男	47	河南			

**SECRET**

5




10



EXAMPLE 42

(2-[4-[3-(1-*H*-Imidazol-2-ylamino)-propoxy]-phenyl]-cyclopropyl)-acetic  
acid

5



The title compound is prepared according to the general procedures described in SCHEME 9.


10

05002106 061504  
F05F00 33123960

EXAMPLE 43

(2-{3-Fluoro-4-[3-(1-*H*-imidazol-2-ylamino)-propoxy]-phenyl}-cyclopropyl)-  
acetic acid

5




The title compound is prepared according to the general procedures  
described in SCHEME 9.

10

FOI 302 30120060

-137

5




10

1. NAME \_\_\_\_\_  
 2. ADDRESS \_\_\_\_\_  
 3. CITY \_\_\_\_\_  
 4. STATE \_\_\_\_\_  
 5. ZIP \_\_\_\_\_  
 6. PHONE \_\_\_\_\_  
 7. DATE \_\_\_\_\_  
 8. SIGNATURE \_\_\_\_\_  
 9. PRINT NAME \_\_\_\_\_  
 10. PRINT ADDRESS \_\_\_\_\_  
 11. PRINT CITY \_\_\_\_\_  
 12. PRINT STATE \_\_\_\_\_  
 13. PRINT ZIP \_\_\_\_\_  
 14. PRINT PHONE \_\_\_\_\_  
 15. PRINT DATE \_\_\_\_\_  
 16. PRINT SIGNATURE \_\_\_\_\_  
 17. PRINT NAME \_\_\_\_\_  
 18. PRINT ADDRESS \_\_\_\_\_  
 19. PRINT CITY \_\_\_\_\_  
 20. PRINT STATE \_\_\_\_\_  
 21. PRINT ZIP \_\_\_\_\_  
 22. PRINT PHONE \_\_\_\_\_  
 23. PRINT DATE \_\_\_\_\_  
 24. PRINT SIGNATURE \_\_\_\_\_  
 25. PRINT NAME \_\_\_\_\_  
 26. PRINT ADDRESS \_\_\_\_\_  
 27. PRINT CITY \_\_\_\_\_  
 28. PRINT STATE \_\_\_\_\_  
 29. PRINT ZIP \_\_\_\_\_  
 30. PRINT PHONE \_\_\_\_\_  
 31. PRINT DATE \_\_\_\_\_  
 32. PRINT SIGNATURE \_\_\_\_\_  
 33. PRINT NAME \_\_\_\_\_  
 34. PRINT ADDRESS \_\_\_\_\_  
 35. PRINT CITY \_\_\_\_\_  
 36. PRINT STATE \_\_\_\_\_  
 37. PRINT ZIP \_\_\_\_\_  
 38. PRINT PHONE \_\_\_\_\_  
 39. PRINT DATE \_\_\_\_\_  
 40. PRINT SIGNATURE \_\_\_\_\_  
 41. PRINT NAME \_\_\_\_\_  
 42. PRINT ADDRESS \_\_\_\_\_  
 43. PRINT CITY \_\_\_\_\_  
 44. PRINT STATE \_\_\_\_\_  
 45. PRINT ZIP \_\_\_\_\_  
 46. PRINT PHONE \_\_\_\_\_  
 47. PRINT DATE \_\_\_\_\_  
 48. PRINT SIGNATURE \_\_\_\_\_  
 49. PRINT NAME \_\_\_\_\_  
 50. PRINT ADDRESS \_\_\_\_\_  
 51. PRINT CITY \_\_\_\_\_  
 52. PRINT STATE \_\_\_\_\_  
 53. PRINT ZIP \_\_\_\_\_  
 54. PRINT PHONE \_\_\_\_\_  
 55. PRINT DATE \_\_\_\_\_  
 56. PRINT SIGNATURE \_\_\_\_\_  
 57. PRINT NAME \_\_\_\_\_  
 58. PRINT ADDRESS \_\_\_\_\_  
 59. PRINT CITY \_\_\_\_\_  
 60. PRINT STATE \_\_\_\_\_  
 61. PRINT ZIP \_\_\_\_\_  
 62. PRINT PHONE \_\_\_\_\_  
 63. PRINT DATE \_\_\_\_\_  
 64. PRINT SIGNATURE \_\_\_\_\_  
 65. PRINT NAME \_\_\_\_\_  
 66. PRINT ADDRESS \_\_\_\_\_  
 67. PRINT CITY \_\_\_\_\_  
 68. PRINT STATE \_\_\_\_\_  
 69. PRINT ZIP \_\_\_\_\_  
 70. PRINT PHONE \_\_\_\_\_  
 71. PRINT DATE \_\_\_\_\_  
 72. PRINT SIGNATURE \_\_\_\_\_  
 73. PRINT NAME \_\_\_\_\_  
 74. PRINT ADDRESS \_\_\_\_\_  
 75. PRINT CITY \_\_\_\_\_  
 76. PRINT STATE \_\_\_\_\_  
 77. PRINT ZIP \_\_\_\_\_  
 78. PRINT PHONE \_\_\_\_\_  
 79. PRINT DATE \_\_\_\_\_  
 80. PRINT SIGNATURE \_\_\_\_\_  
 81. PRINT NAME \_\_\_\_\_  
 82. PRINT ADDRESS \_\_\_\_\_  
 83. PRINT CITY \_\_\_\_\_  
 84. PRINT STATE \_\_\_\_\_  
 85. PRINT ZIP \_\_\_\_\_  
 86. PRINT PHONE \_\_\_\_\_  
 87. PRINT DATE \_\_\_\_\_  
 88. PRINT SIGNATURE \_\_\_\_\_  
 89. PRINT NAME \_\_\_\_\_  
 90. PRINT ADDRESS \_\_\_\_\_  
 91. PRINT CITY \_\_\_\_\_  
 92. PRINT STATE \_\_\_\_\_  
 93. PRINT ZIP \_\_\_\_\_  
 94. PRINT PHONE \_\_\_\_\_  
 95. PRINT DATE \_\_\_\_\_  
 96. PRINT SIGNATURE \_\_\_\_\_  
 97. PRINT NAME \_\_\_\_\_  
 98. PRINT ADDRESS \_\_\_\_\_  
 99. PRINT CITY \_\_\_\_\_  
 100. PRINT STATE \_\_\_\_\_  
 101. PRINT ZIP \_\_\_\_\_  
 102. PRINT PHONE \_\_\_\_\_  
 103. PRINT DATE \_\_\_\_\_  
 104. PRINT SIGNATURE \_\_\_\_\_  
 105. PRINT NAME \_\_\_\_\_  
 106. PRINT ADDRESS \_\_\_\_\_  
 107. PRINT CITY \_\_\_\_\_  
 108. PRINT STATE \_\_\_\_\_  
 109. PRINT ZIP \_\_\_\_\_  
 110. PRINT PHONE \_\_\_\_\_  
 111. PRINT DATE \_\_\_\_\_  
 112. PRINT SIGNATURE \_\_\_\_\_  
 113. PRINT NAME \_\_\_\_\_  
 114. PRINT ADDRESS \_\_\_\_\_  
 115. PRINT CITY \_\_\_\_\_  
 116. PRINT STATE \_\_\_\_\_  
 117. PRINT ZIP \_\_\_\_\_  
 118. PRINT PHONE \_\_\_\_\_  
 119. PRINT DATE \_\_\_\_\_  
 120. PRINT SIGNATURE \_\_\_\_\_  
 121. PRINT NAME \_\_\_\_\_  
 122. PRINT ADDRESS \_\_\_\_\_  
 123. PRINT CITY \_\_\_\_\_  
 124. PRINT STATE \_\_\_\_\_  
 125. PRINT ZIP \_\_\_\_\_  
 126. PRINT PHONE \_\_\_\_\_  
 127. PRINT DATE \_\_\_\_\_  
 128. PRINT SIGNATURE \_\_\_\_\_  
 129. PRINT NAME \_\_\_\_\_  
 130. PRINT ADDRESS \_\_\_\_\_  
 131. PRINT CITY \_\_\_\_\_  
 132. PRINT STATE \_\_\_\_\_  
 133. PRINT ZIP \_\_\_\_\_  
 134. PRINT PHONE \_\_\_\_\_  
 135. PRINT DATE \_\_\_\_\_  
 136. PRINT SIGNATURE \_\_\_\_\_  
 137. PRINT NAME \_\_\_\_\_  
 138. PRINT ADDRESS \_\_\_\_\_  
 139. PRINT CITY \_\_\_\_\_  
 140. PRINT STATE \_\_\_\_\_  
 141. PRINT ZIP \_\_\_\_\_  
 142. PRINT PHONE \_\_\_\_\_  
 143. PRINT DATE \_\_\_\_\_  
 144. PRINT SIGNATURE \_\_\_\_\_  
 145. PRINT NAME \_\_\_\_\_  
 146. PRINT ADDRESS \_\_\_\_\_  
 147. PRINT CITY \_\_\_\_\_  
 148. PRINT STATE \_\_\_\_\_  
 149. PRINT ZIP \_\_\_\_\_  
 150. PRINT PHONE \_\_\_\_\_  
 151. PRINT DATE \_\_\_\_\_  
 152. PRINT SIGNATURE \_\_\_\_\_  
 153. PRINT NAME \_\_\_\_\_  
 154. PRINT ADDRESS \_\_\_\_\_  
 155. PRINT CITY \_\_\_\_\_  
 156. PRINT STATE \_\_\_\_\_  
 157. PRINT ZIP \_\_\_\_\_  
 158. PRINT PHONE \_\_\_\_\_  
 159. PRINT DATE \_\_\_\_\_  
 160. PRINT SIGNATURE \_\_\_\_\_  
 161. PRINT NAME \_\_\_\_\_  
 162. PRINT ADDRESS \_\_\_\_\_  
 163. PRINT CITY \_\_\_\_\_  
 164. PRINT STATE \_\_\_\_\_  
 165. PRINT ZIP \_\_\_\_\_  
 166. PRINT PHONE \_\_\_\_\_  
 167. PRINT DATE \_\_\_\_\_  
 168. PRINT SIGNATURE \_\_\_\_\_  
 169. PRINT NAME \_\_\_\_\_  
 170. PRINT ADDRESS \_\_\_\_\_  
 171. PRINT CITY \_\_\_\_\_  
 172. PRINT STATE \_\_\_\_\_  
 173. PRINT ZIP \_\_\_\_\_  
 174. PRINT PHONE \_\_\_\_\_  
 175. PRINT DATE \_\_\_\_\_  
 176. PRINT SIGNATURE \_\_\_\_\_  
 177. PRINT NAME \_\_\_\_\_  
 178. PRINT ADDRESS \_\_\_\_\_  
 179. PRINT CITY \_\_\_\_\_  
 180. PRINT STATE \_\_\_\_\_  
 181. PRINT ZIP \_\_\_\_\_  
 182. PRINT PHONE \_\_\_\_\_  
 183. PRINT DATE \_\_\_\_\_  
 184. PRINT SIGNATURE \_\_\_\_\_  
 185. PRINT NAME \_\_\_\_\_  
 186. PRINT ADDRESS \_\_\_\_\_  
 187. PRINT CITY \_\_\_\_\_  
 188. PRINT STATE \_\_\_\_\_  
 189. PRINT ZIP \_\_\_\_\_  
 190. PRINT PHONE \_\_\_\_\_  
 191. PRINT DATE \_\_\_\_\_  
 192. PRINT SIGNATURE \_\_\_\_\_  
 193. PRINT NAME \_\_\_\_\_  
 194. PRINT ADDRESS \_\_\_\_\_  
 195. PRINT CITY \_\_\_\_\_  
 196. PRINT STATE \_\_\_\_\_  
 197. PRINT ZIP \_\_\_\_\_  
 198. PRINT PHONE \_\_\_\_\_  
 199. PRINT DATE \_\_\_\_\_  
 200. PRINT SIGNATURE \_\_\_\_\_  
 201. PRINT NAME \_\_\_\_\_  
 202. PRINT ADDRESS \_\_\_\_\_  
 203. PRINT CITY \_\_\_\_\_  
 204. PRINT STATE \_\_\_\_\_  
 205. PRINT ZIP \_\_\_\_\_  
 206. PRINT PHONE \_\_\_\_\_  
 207. PRINT DATE \_\_\_\_\_  
 208. PRINT SIGNATURE \_\_\_\_\_  
 209. PRINT NAME \_\_\_\_\_  
 210. PRINT ADDRESS \_\_\_\_\_  
 211. PRINT CITY \_\_\_\_\_  
 212. PRINT STATE \_\_\_\_\_  
 213. PRINT ZIP \_\_\_\_\_  
 214. PRINT PHONE \_\_\_\_\_  
 215. PRINT DATE \_\_\_\_\_  
 216. PRINT SIGNATURE \_\_\_\_\_  
 217. PRINT NAME \_\_\_\_\_  
 218. PRINT ADDRESS \_\_\_\_\_  
 219. PRINT CITY \_\_\_\_\_  
 220. PRINT STATE \_\_\_\_\_

### EXAMPLE 45

(2-[4-[3-(3-*H*-Imidazol-4-ylamino)-propoxy]-phenyl]-cyclopropyl)-acetic  
acid

5



The title compound is prepared according to the general procedures described in SCHEME 9.


10

[illegible]

-139-

EXAMPLE 46

(2-[4-[3-(1-*H*-Pyrazol-3-ylamino)-propoxy]-phenyl]-cyclopropyl)-acetic acid



5

The title compound is prepared according to the general procedures described in SCHEME 9.


10

0906166-06101  
F05F90-98F28860

EXAMPLE 47

(2-{3-Fluoro-4-[3-(1-*H*-pyrazol-3-ylamino)-propoxy]-phenyl}-cyclopropyl)-  
acetic acid

5



The title compound is prepared according to the general procedures described in SCHEME 9.

10


06602406, 061504  
FOI 2008-00120000

-141-

EXAMPLE 48

(1-Methyl-2-{4-[2-(6-methylamino-pyridin-2-yl)-ethoxy]-phenyl}-  
cyclopropyl)-acetic acid

5



The title compound is prepared according to the general procedures  
described in SCHEME 10.

10


05082106-001501  
105100

-142-

EXAMPLE 49

(2-{4-[2-(6-Ethylamino-pyridin-2-yl)-ethoxy]-phenyl}-1-methyl-cyclopropyl)-  
acetic acid

5



The title compound is prepared according to the general procedures described, in SCHEME 10.

10

00002106 051701  
F02F90 90F20060


-143-



### EXAMPLE 50

[2-(4-[2-[6-(2-Methoxy-ethylamino)-pyridin-2-yl]-ethoxy]-phenyl)-1-methyl-cyclopropyl]-acetic acid

5



The title compound is prepared according to the general procedures described in SCHEME 10.


[illegible]

- 1244 -

**EXAMPLE 51**

**[2-(4-{2-[6-(3-Methoxy-propylamino)-pyridin-2-yl]-ethoxy}-phenyl)-1-methyl-cyclopropyl]-acetic acid**

5



The title compound is prepared according to the general procedures described in SCHEME 10.

10


09692106-001501

-145-

EXAMPLE 52

(2-{4-[2-(6-Acetylamino-pyridin-2-yl)-ethoxy]-phenyl}-1-methyl-cyclopropyl)-acetic acid

5



The title compound is prepared according to the general procedures described in SCHEME 10.

10


09002406-061501  
09002406-061501

-146-

EXAMPLE 53

(2-{4-[2-(6-Acetyl-amino-pyridin-2-yl)-ethoxy]-phenyl}-cyclopropyl)-acetic  
acid

5



The title compound is prepared according to the general procedures described in SCHEME 10.

10.

05062135 "061501  
T05190 99129960

-147-

The activity of the compounds of the present invention was tested in the following assays.

### VITRONECTIN ADHESION ASSAY

#### MATERIALS

Human vitronectin receptors  $\alpha_v\beta_3$  and  $\alpha_v\beta_5$  were purified from human placenta as previously described [Pytela et al., Methods in Enzymology, 144:475-489 (1987)]. Human vitronectin was purified from fresh frozen plasma as previously described [Yatohgo et al., Cell Structure and Function, 13:281-292 (1988)]. Biotinylated human vitronectin was prepared by coupling NHS-biotin from Pierce Chemical Company (Rockford, IL) to purified vitronectin as previously described [Charo et al., J. Biol. Chem., 266(3):1415-1421 (1991)]. Assay buffer, OPD substrate tablets, and RIA grade BSA were obtained from Sigma (St. Louis, MO). Anti-biotin antibody was obtained from Sigma (St. Louis, MO). Nalge Nunc-Immuno microtiter plates were obtained from Nalge Company (Rochester, NY).

#### METHODS

##### Solid Phase Receptor Assays

This assay was essentially the same as previously reported [Niiya et al., Blood, 70:475-483 (1987)]. The purified human vitronectin receptors  $\alpha_v\beta_3$  and  $\alpha_v\beta_5$  were diluted from stock solutions to 1.0  $\mu\text{g/mL}$  in Tris-buffered saline containing 1.0 mM  $\text{Ca}^{++}$ ,  $\text{Mg}^{++}$ , and  $\text{Mn}^{++}$ , pH 7.4 ( $\text{TBS}^{+++}$ ). The diluted receptors were immediately transferred to Nalge Nunc-Immuno microtiter plates at 100  $\mu\text{L/well}$  (100 ng receptor/well). The plates were sealed and incubated overnight at 4°C to allow the receptors to bind to the wells. All remaining steps were at room temperature. The assay plates were emptied and 200  $\mu\text{L}$  of 1% RIA grade BSA in  $\text{TBS}^{+++}$  ( $\text{TBS}^{+++}/\text{BSA}$ ) were added to block exposed plastic surfaces. Following a 2 hour incubation, the assay plates were washed with  $\text{TBS}^{+++}$  using a 96 well plate

-148-

03062106-061501  
F05F90-98F2B250

washer. Logarithmic serial dilution of the test compound and controls were made starting at a stock concentration of 2 mM and using 2 nM biotinylated vitronectin in TBS<sup>++</sup>/BSA as the diluent. This premixing of labeled ligand with test (or control) ligand, and subsequent transfer of 50  $\mu$ L aliquots to the assay plate was carried out with a CETUS Propette robot; the final concentration of the labeled ligand was 1 nM and the highest concentration of test compound was  $1.0 \times 10^{-4}$  M. The competition occurred for two hours after which all wells were washed with a plate washer as before. Affinity purified horseradish peroxidase labeled goat anti-biotin antibody was diluted 1:2000 in TBS<sup>++</sup>/BSA and 125  $\mu$ L was added to each well. After 45 minutes, the plates were washed and incubated with OPD/H<sub>2</sub>O<sub>2</sub> substrate in 100 mM/L Citrate buffer, pH 5.0. The plate was read with a microtiter plate reader at a wavelength of 450 nm and when the maximum-binding control wells reached an absorbance of about 1.0, the final A<sub>450</sub> were recorded for analysis. The data were analyzed using a macro written for use with the EXCEL spreadsheet program. The mean, standard deviation, and %CV were determined for duplicate concentrations. The mean A<sub>450</sub> values were normalized to the mean of four maximum-binding controls (no competitor added)(B-MAX). The normalized values were subjected to a four parameter curve fit algorithm [Rodbard et al., Int. Atomic Energy Agency, Vienna, pp 469 (1977)], plotted on a semi-log scale, and the computed concentration corresponding to inhibition of 50% of the maximum binding of biotinylated vitronectin (IC<sub>50</sub>) and corresponding R<sup>2</sup> was reported for those compounds exhibiting greater than 50% inhibition at the highest concentration tested; otherwise the IC<sub>50</sub> is reported as being greater than the highest concentration tested.  $\beta$ -[[2-[[5-[(aminoiminomethyl)amino]-1-oxopentyl]amino]-1-oxoethyl]amino]-3-pyridinepropanoic acid [US 5,602,155 Example 1] which is a potent  $\alpha_w\beta_3$  antagonist (IC<sub>50</sub> in the range 3-10 nM) was included on each plate as a positive control.

#### PURIFIED IIb/IIIa RECEPTOR ASSAY

#### MATERIALS

-149-

Human fibrinogen receptor (IIb/IIIa) was purified from outdated platelets. (Pytela, R., Pierschbacher, M.D., Argaves, S., Suzuki, S., and Rouslahti, E. "Arginine-Glycine-Aspartic acid adhesion receptors", Methods in Enzymology 144(1987):475-489.) Human vitronectin was purified from  
5 fresh frozen plasma as described in Yatohgo, T., Izumi, M., Kashiwagi, H., and Hayashi, M., "Novel purification of vitronectin from human plasma by heparin affinity chromatography," Cell Structure and Function 13(1988):281-292. Biotinylated human vitronectin was prepared by coupling NHS-biotin from Pierce Chemical Company (Rockford, IL) to  
10 purified vitronectin as previously described. (Charo, I.F., Nannizzi, L., Phillips, D.R., Hsu, M.A., Scarborough, R.M., "Inhibition of fibrinogen binding to GP IIb/IIIa by a GP IIIa peptide", J. Biol. Chem. 266(3)(1991): 1415-1421.) Assay buffer, OPD substrate tablets, and RIA grade BSA were obtained from Sigma (St. Louis, MO). Anti-biotin antibody was obtained  
15 from Sigma (St. Louis, MO). Nalge Nunc-Immuno microtiter plates were obtained from (Rochester, NY). ADP reagent was obtained from Sigma (St. Louis, MO).

## METHODS

20

### Solid Phase Receptor Assays

This assay is essentially the same reported in Niiya, K., Hodson, E., Bader, R., Byers-Ward, V. Koziol, J.A., Plow, E.F. and Ruggeri, Z.M.,  
25 "Increased surface expression of the membrane glycoprotein IIb/IIIa complex induced by platelet activation: Relationships to the binding of fibrinogen and platelet aggregation", Blood 70(1987):475-483. The purified human fibrinogen receptor (IIb/IIIa) was diluted from stock solutions to 1.0  $\mu\text{g/mL}$  in Tris-buffered saline containing 1.0 mM  $\text{Ca}^{++}$ ,  $\text{Mg}^{++}$ , and  $\text{Mn}^{++}$ , pH  
30 7.4 ( $\text{TBS}^{+++}$ ). The diluted receptor was immediately transferred to Nalge Nunc-Immuno microtiter plates at 100  $\mu\text{L/well}$  (100 ng receptor/well). The plates were sealed and incubated overnight at 4°C to allow the receptors to bind to the wells. All remaining steps were at room temperature. The assay plates were emptied and 200  $\mu\text{L}$  of 1% RIA grade BSA in  $\text{TBS}^{+++}$

-150-





